Biosynex agrees to sell molecular biology unit for €4 million amid safeguard proceedings
STRASBOURG: Biosynex, a French diagnostic testing group, has secured a firm commitment from an unnamed pharmaceutical industry buyer to purchase its in-house molecular biology business for about €4 million, the company announced May 25. The sale remains subject to approval by the court-appointed liquidator overseeing…